EA201790791A1 - Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов - Google Patents

Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов

Info

Publication number
EA201790791A1
EA201790791A1 EA201790791A EA201790791A EA201790791A1 EA 201790791 A1 EA201790791 A1 EA 201790791A1 EA 201790791 A EA201790791 A EA 201790791A EA 201790791 A EA201790791 A EA 201790791A EA 201790791 A1 EA201790791 A1 EA 201790791A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulphates
lipids
accumulation
treat
conditions associated
Prior art date
Application number
EA201790791A
Other languages
English (en)
Other versions
EA034524B1 (ru
Inventor
Шуньлинь Жэнь
Цзинь Коунг Ким
Original Assignee
Вирджиния Коммонвелт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вирджиния Коммонвелт Юниверсити filed Critical Вирджиния Коммонвелт Юниверсити
Publication of EA201790791A1 publication Critical patent/EA201790791A1/ru
Publication of EA034524B1 publication Critical patent/EA034524B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Предоставлены способы и композиции для предупреждения и/или лечения симптомов, ассоциированных с расстройствами накопления липидов, вызываемыми пониженной лептиновой активностью и аномальным накоплением липидов. Эти способы включают введение по меньшей мере одного сульфата окисленного холестерина (OCS) индивидууму с указанным расстройством. Расстройство может быть приобретенным или врожденным (наследственным).
EA201790791A 2014-10-10 2015-10-13 Сульфаты окисленного холестерина для лечения пониженной лептиновой активности EA034524B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062260P 2014-10-10 2014-10-10
PCT/US2015/055262 WO2016058000A1 (en) 2014-10-10 2015-10-13 Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder

Publications (2)

Publication Number Publication Date
EA201790791A1 true EA201790791A1 (ru) 2017-08-31
EA034524B1 EA034524B1 (ru) 2020-02-17

Family

ID=54478210

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790791A EA034524B1 (ru) 2014-10-10 2015-10-13 Сульфаты окисленного холестерина для лечения пониженной лептиновой активности

Country Status (12)

Country Link
US (4) US20170252355A1 (ru)
EP (1) EP3204013A1 (ru)
JP (2) JP2017530174A (ru)
KR (1) KR20170066507A (ru)
CN (1) CN107106576A (ru)
AU (3) AU2015329716A1 (ru)
BR (1) BR112017007025A2 (ru)
CA (1) CA2962500A1 (ru)
EA (1) EA034524B1 (ru)
IL (1) IL251290A0 (ru)
MX (1) MX2017004658A (ru)
WO (1) WO2016058000A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
SI3086793T1 (sl) 2013-12-24 2022-10-28 Virginia Commonwealth University Uporaba oksigeniranih holesterol sulfatov (OCS) za zdravljenje ledvične disfunkcije
AU2017255959B2 (en) * 2016-04-29 2020-10-15 Zevra Denmark A/S Arimoclomol for treating glucocerebrosidase associated disorders
CA3031224A1 (en) 2016-08-02 2018-02-08 Shunlin Ren Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
TW201818946A (zh) * 2016-08-02 2018-06-01 美商杜瑞克公司 包含至少一種氧化膽固醇硫酸鹽及至少一種聚烯烴二醇、羧甲基纖維素及聚氧甘油酯之組成物及彼等之使用方法
US20200276211A1 (en) * 2017-11-28 2020-09-03 Viewpoint Therapeutics, Inc. Compounds for treating near vision disorders
JP2023531735A (ja) * 2020-06-26 2023-07-25 デュレクト コーポレーション インスリン抵抗性、糖尿病、及び前糖尿病の少なくとも１つを処置するための酸素化コレステロールスルフェート類の使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2007095462A2 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EA026683B1 (ru) 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА

Also Published As

Publication number Publication date
MX2017004658A (es) 2017-07-17
JP2021008506A (ja) 2021-01-28
CA2962500A1 (en) 2016-04-14
WO2016058000A1 (en) 2016-04-14
EP3204013A1 (en) 2017-08-16
BR112017007025A2 (pt) 2017-12-12
EA034524B1 (ru) 2020-02-17
US20200138831A1 (en) 2020-05-07
AU2015329716A1 (en) 2017-04-13
US20210161913A1 (en) 2021-06-03
CN107106576A (zh) 2017-08-29
AU2021200574A1 (en) 2021-03-04
JP2017530174A (ja) 2017-10-12
US20190083509A1 (en) 2019-03-21
AU2021202288A1 (en) 2021-05-13
IL251290A0 (en) 2017-05-29
US20170252355A1 (en) 2017-09-07
KR20170066507A (ko) 2017-06-14

Similar Documents

Publication Publication Date Title
EA201790791A1 (ru) Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов
IL288712B1 (en) Methods for treating abnormal movement disorders
NZ720949A (en) Methods and compositions for treating aging-associated conditions
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MX2017007852A (es) Formulaciones de acido hipocloroso y metodos para tratar afecciones de la piel.
MX2021008044A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
NZ755605A (en) Compositions for modulating tau expression
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2022003128A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
HK1258696A1 (zh) 治療或預防皮膚障礙的新型組合物和方法
HUE049518T2 (hu) Készítmények és eljárások a szem megbetegedéseinek kezelésére és diagnosztizálására
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
MX2017014095A (es) Uso de cd24 para disminuir los niveles de colesterol de las lipoproteinas de baja densidad.
EP3310353A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
MX2017003892A (es) Tratamiento del sindrome de rett.
MX362391B (es) Métodos de tratamiento de enfermedad renal y otros trastornos.
EP3481432A4 (en) DIAGNOSIS OF DISEASES ASSOCIATED WITH THE COL6 GENE AND RELATED METHODS OF TREATMENT
EP3307775A4 (en) Methods for diagnosing and treating affective disorders
WO2015113041A3 (en) Compositions and methods for treating autoimmune and inflammatory diseases
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
EP3177316A4 (en) Method for preventing or treating ocular disorders
IN2013MU03429A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM